Table 5 Main pharmacokinetic parameters (mean ± SD) following oral single administration of either DSV/TAM to rats, compared with their co-administration (n = 5).

From: Development and validation of UPLC-MS/MS method for studying the pharmacokinetic interaction of dasabuvir and tamoxifen, 4-hydroxytamoxifen in Wistar rats

 

Single administration

Co-administration

DSV

TAM

TOH

DSV

TAM

TOH

Cmax

(ng/mL)

144.04 ± 26.50

306.97 ± 108.56

171.62 ± 54.00

158.98 ± 49.00

287.52 ± 81.05

163.67 ± 54.50

tmax

(h)

4.95 ± 1.07

2.03 ± 0.95

2.03 ± 0.95

4.98 ± 0.61

3.03 ± 0.66

5.03 ± 0.66*

t½

(h)

17.95 ± 5.93

15.75 ± 5.18

28.85 ± 1.98

19.72 ± 5.41

17.67 ± 3.42

19.72 ± 1.41

AUC0-∞ (ng.h/mL)

4268.14 ± 754.40

3878.94 ± 406.62

4727.49 ± 774.18

4662.32 ± 686.97

3507.87 ± 463.83

4547.03 ± 913.49

CL/F

(mL/h/kg)

1.70 ± 6.81

2.62 ± 1.53

2.12 ± 1.03

10.89 ± 7.49

2.82 ± 0.88

2.19 ± 0.46

R.B.(%)a

—

—

—

109 ± 11.50

90 ± 8.55

96 ± 9.22

M.R.(%)b

—

—

121.86 ± 11

—

—

129.65 ± 10.88

  1. *Indicates significant difference as compared with the corresponding single administration; group I for DSV, group II for TAM and TOH. (p = 0.05)
  2. aRelative bioavailability calculated by the ratio of AUC0-∞of each drug following co-administration of DSV and TAM, as compared with the single administration.
  3. bMetabolite ratio calculated by the ratio of AUC0-∞ of TOH to that of TAM following co-administration of DSV and TAM, as compared with the single TAM administration.
Back to article page